Cryo-Cell International, Inc. - 10-K Summary (Fiscal Year Ended Nov 30, 2008)
Business Context and Reporting Period
Cryo-Cell International, Inc. is a smaller reporting company engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'elle). The company operates a cGMP/cGTP-compliant facility in Oldsmar, Florida, and holds over 175,000 cord blood specimens worldwide through its own operations and global affiliates. This report covers the fiscal year ended November 30, 2008.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Revenue | $17,278,058 | $17,460,196 |
| Net Loss | $(760,419) | $(5,005,415) |
| Loss Per Share (Basic) | $(0.06) | $(0.43) |
| Cost of Sales | $6,113,514 (35% of revenue) | $6,592,145 (38% of revenue) |
| Operating Cash Flow | $614,163 (Positive) | $(3,404,396) (Negative) |
| Cash and Equivalents (End of Period) | $3,566,366 | $3,364,711 |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Improved Profitability: The net loss decreased significantly by approximately 85% (from $5.0M to $0.76M) due to a 25% reduction in marketing, general, and administrative expenses and a 64% decrease in R&D expenses.
- Revenue Stability: Total revenue declined slightly by 1% to $17.3M. This was driven by an 8% decrease in specimens processed, partially offset by a 13% increase in recurring annual storage fee revenue.
- Expense Reductions: Marketing and administrative expenses dropped from $14.5M to $10.8M, largely due to reduced professional fees (down 61%) and public relations costs (down 50%) following a proxy contest in the prior year.
- Cash Flow Turnaround: The company generated positive operating cash flow of $614,000 in 2008, reversing a negative cash flow of $3.4M in 2007.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that current cash, marketable securities, and operating cash flows will be sufficient to fund operations for at least the next 12 months. The company plans to fund future capital expenditures (approx. $250,000) from operations.
- Strategic Focus: Continued focus on the C'elle menstrual stem cell service, launched in late 2007, and expanding international licensing agreements (Mexico, India, Venezuela).
- Risks:
- Market Acceptance: Success depends on the commercial viability of stem cell therapies and consumer awareness, which remains low.
- Competition: Faces competition from ~25 other private banks and public banks, some with greater financial resources.
- Regulatory: Subject to FDA regulations (cGTP/cGMP) and potential state licensing requirements.
- Revenue Sharing Agreements (RSAs): The company has long-term liabilities related to RSAs where a percentage of future storage revenue is shared with investors. Payments totaled $1.15M in 2008 and are recorded as interest expense.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of recurring storage fees versus one-time processing fees, noting the 8% decline in new specimens processed.
- International Licensing: Review the terms and collectability of international license agreements (Mexico, India, Venezuela) which contributed $897,618 to licensee income.
- Revenue Sharing Liabilities: Assess the long-term impact of the $3.75M liability associated with Revenue Sharing Agreements and the resulting interest expense.
- C'elle Commercialization: Evaluate the progress of the C'elle menstrual stem cell service, as it is currently in a "soft launch" phase with no assurance of future therapeutic development or market acceptance.
- Legal Proceedings: Confirm the final status of the PharmaStem patent litigation (resolved in Cryo-Cell's favor) and the Delaware Chancery Court proxy dispute (resolved via special meeting).